Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.

[1]  R. D. de Man,et al.  Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. , 2009, Journal of hepatology.

[2]  Qing-ling Li,et al.  Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. , 2009, Antiviral research.

[3]  M. Manns,et al.  Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN – , 2022 .

[4]  [EASL clinical practice guidelines. Management of chronic hepatitis B]. , 2009, Gastroenterologie clinique et biologique.

[5]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.

[6]  M. Buti,et al.  TWO YEAR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AND ADEFOVIR DIPIVOXIL (ADV) SWITCH DATA IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102), PRELIMINARY ANALYSIS , 2008 .

[7]  H. Tillmann,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.

[8]  F. Zoulim,et al.  Hepatitis B: reflections on the current approach to antiviral therapy. , 2008, Journal of hepatology.

[9]  P. Marcellin,et al.  Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. , 2007, Annals of internal medicine.

[10]  Yoshiyuki Suzuki,et al.  Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[11]  G. Harb,et al.  [516] A RANDOMIZED TRIAL OF SWITCHING TO TELBIVUDINE VERSUS CONTINUED LAMIVUDINE IN ADULTS WITH CHRONIC HEPATITIS B: RESULTS OF THE PRIMARY ANALYSIS AT WEEK 24 , 2007 .

[12]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[13]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[14]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.